Laboratorios Farmaceuticos Rovi, S.A. reports 1H results

Seeking Alpha ·

Laboratorios Farmaceuticos Rovi, S.A. press release ( LABFF ): 1H revenue of €344.2M (+9.4% Y/Y) misses by €33.41M . EBITDA grew 85.00% year-over-year to reach €121.20M. CDMO sales grew 38.00% year-over-year to reach €106.30M . Net profit surged to €84.40M from €39.70M, while gross margin expanded by 6.50 pp to 68.90%. Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q2 2026 Earnings Call Transcript Laboratorios Farmaceuticos Rovi, S.A. 2026 Q2 - Results - Earnings Call Presentation Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q1 2026 Earnings Call Transcript Historical earnings data for Laboratorios Farmaceuticos Rovi, S.A. Dividend scorecard for Laboratorios Farmaceuticos Rovi, S.A.

AI 시장 분석

For the first half, LABFF reported revenue of 344.2 million euros, up 9.4% year-over-year, but missing market expectations by 33.41 million euros. Conversely, EBITDA surged 85% to 121.2 million euros, and net income expanded significantly to 84.4 million euros. Despite the revenue miss, positive evaluations of the earnings continue, driven by profitability and high growth in the CDMO segment. Investors should focus on margin improvements and the growth potential of the CDMO business rather than the short-term revenue miss.

상승 영향

하락 영향

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 58% · Bearish (Short) 42%

251 participants

Related News

원문 보기 — Seeking Alpha